LSTA Q4 2016 Earnings — Lisata Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

LSTALisata Therapeutics, Inc.

$44M

Q4 2016 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$10M+34.6% YoY

Gross Profit

$931,2819.2% margin

Operating Income

-$6M-58.1% margin

Net Income

-$6M-58.5% margin

EPS (Diluted)

$-13.65

QoQ Revenue Growth

+9.2%

Cash Flow

Operating Cash Flow

-$3M

Free Cash Flow

-$4M

Stock-Based Comp.

$328,675

Balance Sheet

Total Assets

$52M

Total Liabilities

$48M

Stockholders' Equity

$5M

Cash & Equivalents

$15M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$10M	$8M	+34.6%
Gross Profit	$931,281	$1M	-32.4%
Operating Income	-$6M	-$60M	+90.1%
Net Income	-$6M	-$33M	+82.1%